Absci (ABSI) vs Incyte (INCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Absci (ABSI) has outperformed Incyte (INCY) over the past year, gaining 153.4% versus a gain of 33.1%. Over five years, INCY leads with a +72.0% price change compared with -15.9% for ABSI. Incyte is the larger company by market cap ($22.86 billion vs $1.74 billion), about 13.1 times the size.
Incyte converts more of its revenue into profit, with a net margin of 25.0% versus -4113.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | INCY |
|---|---|---|
| Share price | $10.16 | $112.79 |
| Market cap | $1.74B | $22.86B |
| 1-day change | +13.65% | +0.04% |
| YTD return | +191.12% | +14.19% |
| 1-year return | +153.37% | +33.09% |
| 5-year return | -15.90% | +72.04% |
| P/E ratio (TTM) | — | 14.35 |
| Forward P/E | — | 12.89 |
| EPS (TTM) | $-0.79 | $7.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $5.14B |
| Revenue growth (YoY) | -38.24% | +21.22% |
| Net income (latest FY) | $-115.18M | $1.29B |
| Gross margin | — | 92.76% |
| Operating margin | -4297.04% | 29.46% |
| Net margin | -4113.68% | 25.03% |
| 52-week high | $12.06 | $132.60 |
| 52-week low | $2.24 | $82.82 |
| Distance from 52-week high | -15.72% | -14.94% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +41.73% | +14.49% |
| Average volume | 3.45M | 1.63M |
| Shares outstanding | 171.61M | 202.70M |
| Employees | 140 | 2,844 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 13.1 times larger than Absci by market value ($22.86B vs $1.74B).
- ABSI has outperformed INCY by 120.3 percentage points over the past year.
- Incyte is more profitable, keeping 25.0 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
- Incyte grew revenue faster in its latest fiscal year (+21.22% vs -38.24%).
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
ABSI vs INCY FAQ
Which is bigger, Absci or Incyte?
Incyte (INCY) is larger, with a market capitalization of $22.86B compared with $1.74B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or INCY?
ABSI returned +153.37% over the past 12 months, compared with +33.09% for INCY (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Incyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.